Synlogic Collaborates with Roche to Evaluate the Combination of SYNB1891 and Tecentriq (atezolizumab) for Advanced Solid Tumors

Shots:                                                                                                                                               

• Roche & Synlogic enter into a clinical collaboration to evaluate the combination therapy of Synlogic’s SYNB1891 with Roche’s Tecentriq (atezolizumab) to treat patients with advanced solid tumors
• Synlogic plans to file an IND for SYNB1891 to the US FDA in H2’19 for the onset of P-I clinical studies evaluating SYNB1891 as monothx. and in combination with Tecentriq (atezolizumab)
• SYNB1891 (administered intratumorally) is a non-pathogenic strain of E.coli, engineered to express a STING agonist & stimulating the innate immune system. Synlogic also developing it as a Synthetic Biotic therapy designed to act locally & providing a systemic effect in patients

Click here to read full press release/ article | Ref: Synlogic | Image: Synlogic